Alzamend Neuro, Inc.
Financial highlights
| Metric | FY 04/30/25 | FY 04/30/24 | FY 04/30/23 | FY 04/30/22 | FY 04/30/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $1.4M | $6.5M | $7.4M | $5.2M | $1.3M |
| Operating expenses | $4.5M | $9.9M | $14.9M | — | — |
| Operating income | -$4.5M | -$9.9M | -$14.9M | -$12.3M | -$5.0M |
| Interest expense | $18,029 | $10,101 | $7,701 | $46,524 | $142,421 |
| Pretax income | -$4.5M | -$9.9M | -$14.9M | -$12.4M | -$5.0M |
| Net income | -$4.5M | -$9.9M | -$14.9M | -$12.4M | -$5.0M |
| Balance Sheet | |||||
| Cash and equivalents | $3.9M | $376,048 | $5.1M | $14.1M | $1.9M |
| Current assets | $4.2M | $455,242 | $5.8M | $14.4M | $2.9M |
| Total assets | $4.6M | $631,588 | $5.9M | $14.5M | $2.9M |
| Current liabilities | — | — | $2.9M | $1.2M | $899,643 |
| Total liabilities | $634,761 | $3.2M | $2.9M | $1.2M | $899,643 |
| Stockholders' equity | $4.0M | -$2.6M | $3.0M | $13.4M | $2.0M |
| Cash Flow Statement | |||||
| Cash from operations | -$6.6M | -$8.3M | -$8.9M | -$6.6M | -$2.7M |
| Depreciation and amortization | $50,740 | $50,740 | $23,066 | $3,549 | — |
| Stock-based compensation | $325,108 | $955,633 | $3.6M | $4.4M | $2.0M |
Shares outstanding 3.8M · Free float 94.2%
Annual filing data through FY ended April 30, 2025; float as of July 15, 2026.